An observational study in Brain Metastases, Bone Metastases and Head and Neck Cancer, sponsored by Aalborg University Hospital. Not yet recruiting at 3 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by Aalborg University Hospital · Observational
The primary aim of this clinical study, 'Dual Energy CT - a tool for delineation of tumor and organs at risk in radiotherapy' (DART) is to evaluate whether dual-energy CT (DECT) is at least as effective as magnetic resonance imaging (MRI) in delineating both tumors and organs at risk (OARs) in patients referred for radiotherapy (RT). This primary aim will be explored in patient groups where the performance of DECT for RT has been described in the literature (but mostly based on signal-to-noise ratio and/or contrast-to-noise ratio), such as brain metastases (sub-cohort 'DART Brain') and head and neck cancer (sub-cohort 'DART H\&N'). Additionally, DART will explore diagnoses not yet studied in the literature, such as bone metastases (sub-cohort 'DART Bone'). If DECT could be demonstrated to achieve delineations for RT in both tumors and OARs that are equally accurate as those based on MRI, it could offer significant advantages by being faster and more cost-effective, making DECT a valuable alternative to MRI in clinical practice. As a secondary aim, the study will evaluate whether DART offers benefits when added to standard RT imaging for tumor and OAR delineation: (1) For lung cancer patients (sub-cohort 'DART Lung'), where MRI scans are typically not valuable due to tumor motion caused by breathing, 'DART Lung' will assess whether DECT performed in breath-hold provides added value compared to the single-energy CT (SECT) scan conducted during free breathing, as used in current clinical practice. (2) For head and neck cancer patients, 'DART H\&N' will evaluate whether DECT offers added value compared to the positron emission tomography (PET)/CT scan currently used in clinical practice.
A detailed description of the study is provided in the uploaded document 'Study Protocol with Statistical Analysis Plan'.
1,960 studies on the registry are indexed under Brain Neoplasms; 515 are open to participants now.
This study's planned enrollment of 80 is below the median of 100 across 380 observational studies indexed under Brain Neoplasms.
Browse Brain Neoplasms studies →Aalborg University Hospital is the lead sponsor of 195 studies on the registry; 39 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Cancer patients referred for radiotherapy at Aalborg University Hospital, Denmark. For the 'DART Bone (SBRT)' cohort, patients are also referred for radiotherapy at Odense University Hospital and Copenhagen University Hospital, Herlev and Gentofte, Denmark
Exclusion Criteria:
Patients with 1-5 brain metastases referred for whole brain radiotherapy. Intervention: Extra DECT scan with iodine-based contrast agent + extra MRI scan with Gadolinium-based contrast agent.
Diagnostic Test: Dual-energy CT (DECT) · Drug: Iodine-based contrast agent · Diagnostic Test: Magnetic Resonance Imaging (MRI) · Drug: Gadolinium-based contrast agent
Patients with 1-5 brain metastases referred for stereotactic radiotherapy. Intervention: Extra DECT scan with iodine-based contrast agent.
Diagnostic Test: Dual-energy CT (DECT) · Drug: Iodine-based contrast agent
Patients with bone metastases without medullary involvement in one or more regions of the vertebral column (C1-C7, Th1-12, L1-L5, Os Sacrum) referred for palliative radiotherapy. Intervention: Extra DECT scan with iodine-based contrast agent + extra MRI scan without contrast agent.
Diagnostic Test: Dual-energy CT (DECT) · Drug: Iodine-based contrast agent · Diagnostic Test: Magnetic Resonance Imaging (MRI)
Patients with bone metastases without medullary involvement in one or more regions of the vertebral column (C1-C7, Th1-12, L1-L5, Os Sacrum) referred for palliative radiotherapy. Intervention: Extra DECT scan with iodine-based contrast agent.
Diagnostic Test: Dual-energy CT (DECT) · Drug: Iodine-based contrast agent
Patients with head and neck cancer referred for radiotherapy. Patients must have undergone a PET/CT scan during the diagnostic evaluation for cancer. Intervention: Extra DECT scan without contrast agent.
Diagnostic Test: Dual-energy CT (DECT)
Patients with lung cancer referred for palliative radiotherapy with a maximum of 10 fractions. Interventions: Extra DECT scan in breath-hold without contrast agent.
Diagnostic Test: Dual-energy CT (DECT)
Additional DECT scan performed for tumor and OAR delineation.
Administered intravenously with DECT for enhanced imaging.
Additional MRI scan performed for tumor and OAR delineation.
Administered intravenously with MRI for enhanced imaging.
Inter-observer variability (geometric differences in volume and surface) of manual tumor and OAR delineations on DECT compared with SECT/MRI.
For patients enrolled in cohorts 'DART Brain', 'DART Bone' and 'DART H\&N', the accuracy of manual delineations of tumors and OARs on DECT scans will be compared to those manually performed on a combination of SECT and MRI scans for each patient. For patients enrolled in 'DART H\&N' the comparison will also be done to the PET/CT scan. A reduction in inter-observer variability in delineations will serve as an indicator of improved contour accuracy for both tumors and OARs. Inter-observer variability for tumor and OAR delineations on DECT and SECT/MRI scans, respectively, will be measured as geometric differences between individual manual delineations and consensus structures for each tumor and OAR. Consensus structures will be generated on both DECT and SECT/MRI scans using the STAPLE function with a 50% agreement threshold. Variations relative to the consensus structures will be reported using various metrics, including volume and surface differences.
Time frame: Baseline (time of imaging before radiotherapy planning)
Qualitative image-quality assessment of tumors and OARs using a Likert scale (or comparable method) for DECT compared with SECT/MRI.
The secondary outcome will be measured in all patient cohorts ('DART Brain', 'DART Bone', 'DART H\&N', and 'DART Lung'). Image-quality for tumors and OARs will be evaluated qualitatively by experienced oncologists using a Likert scale or comparable method, and evaluations will be made and reported between DECT and SECT/MRI scans (and, for patients enrolled in 'DART H\&N', also PET/CT scans).
Time frame: Baseline (time of imaging before radiotherapy planning)
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aalborg University Hospital